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Rats affected by the MENX multitumor syndrome develop pheochromocytoma (100%). Pheochromocytomas are uncommon
tumors and animal models are scarce, hence the interest in MENX rats to identify and preclinically evaluate novel targeted
therapies. A prerequisite for such studies is a sensitive and noninvasive detection of MENXassociated pheochromocytoma.
We performed positron emission tomography (PET) to determine whether rat pheochromocytomas are detected by tracers
used in clinical practice, such as 68Ga-DOTATOC (somatostatin analogue) or 11C-Hydroxyephedrine (HED), a norepinephrine
analogue. We analyzed four affected and three unaffected rats. The PET scan findings were correlated to histopathology and
immunophenotype of the tumors, their proliferative index, and the expression of genes coding for somatostatin receptors or
the norepinephrine transporter. We observed that mean 68Ga-DOTATOC standard uptake value (SUV) in adrenals of affected
animals was 23.3 ± 3.9, significantly higher than in control rats (15.4 ± 7.9; P = .03). The increase in mean tumor-to-liver ratio
of 11C-HED in the MENX-affected animals (1.6 ± 0.5) compared to controls (0.7 ± 0.1) was even more significant (P = .0016).
In a unique animal model, functional imaging depicting two pathways important in pheochromocytoma biology discriminated
affected animals from controls, thus providing the basis for future preclinical work with MENX rats.
1. Introduction
Pheochromocytomas are rare neuroendocrine tumors that
arise from adrenal chromaffin cells. Secretion of cate-
cholamines by pheochromocytomas may result in clinical
hypertension which is potentially life-threatening to patients.
Up to 10% of pheochromocytomas will undergo malignant
transformation with metastatic spread mainly to the bones
and liver [1, 2]. Once metastasized, there is no curative
treatment for this disease.
Diagnosis of pheochromocytoma usually involves, at
the biochemical level, the measurement of plasma or urine
content of catecholamines and their metabolites, and at the
macroscopic level morphological appearance with radiologic
imaging, such as computed tomography and magnetic
resonance tomography. More recently, functional imaging
using for example, ligands specific for catecholamine uptake,
synthesis/secretion pathways, or endocrine cell surface recep-
tors has been applied for pheochromocytoma detection, in
addition to classical morphological imaging and biochemicals
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tests, to increase sensitivity and accuracy [3]. Since clinical,
biochemical, and anatomic appearance may not with cer-
tainty distinguish between malignant and benign tumors,
functional imaging might add critical information pre- and
postoperatively improving patient management.
The main therapeutic target for pheochromocytoma is
surgical tumor elimination or reduction and control of
symptoms of excessive catecholamine secretion. Currently,
the best adjunctive therapy in malignant and metastasized
pheochromocytoma is treatment with radiopharmaceuticals
such as 131I-metaiodobenzylguanidine (131I-MIBG), which
takes advantage of the norepinephrine transport system of
adrenal chromaffin cells [4, 5]. However, although it often
achieves successful palliation, 131I-MIBG therapy has limited
effect on tumor control and it is generally not curative [6, 7].
To develop effective anticancer treatments, it is necessary
to have available suitable preclinical models to test novel
agents and to monitor their effectiveness against the tumor.
This is especially important for uncommon tumors, such as
pheochromocytoma, where comprehensive clinical trials are
often difficult to set up and carry to completion. In a spon-
taneous rat model of multiple endocrine neoplasia, named
MENX, pheochromocytoma develops in the affected animals
with complete penetrance (100%). A clear progression from
adrenal medullary hyperplasia to adenoma is evident [8].
This syndrome is inherited as a recessive trait and is caused by
a germline mutation of the cell cycle regulatory gene Cdkn1b,
encoding p27Kip1 [9].
In the current study, we sought to identify an imaging
modality that would allow us to sensitively detect the adrenal
tumors that occur in the MENX-affected rats. We here
demonstrate that adrenal lesions can be detected by 11C-
HED, a tracer that takes advantage of the norepinephrine
transport system which is expressed in adrenal chromaffin
cells. Detection of these neuroendocrine tumors is also pos-
sible with a somatostatin receptor ligand (68Ga-DOTATOC).
Quantification of distinct functional parameters in this ani-
mal model of pheochromocytoma is a prerequisite to exploit
this system for the preclinical testing of novel treatment
regimens in vivo and for the evaluation of novel imaging
modalities. Based on our findings, 11C-HED-PET could be
used to monitor noninvasively tumor behaviour following
treatment of MENX rats with antitumor drugs, allowing
repeated investigations of the same animals throughout the
treatment procedure.
2. Materials and Methods
2.1. Animals. The MENX phenotype was initially identified
in a Sprague Dawley (SD) rat colony and maintained as
previously reported [8]. Affected rats are homozygous for a
germline frameshift mutation in the Cdkn1b gene (p27Kip1)
and are hereafter indicated as affected or mut/mut [9]. The
affected rats spontaneously develop pheochromocytoma and
other neuroendocrine tumors [8]. Animals were maintained
in agreement with general husbandry rules approved by
the Helmholtz Zentrum Mu¨nchen. Rats were treated in
accordance with the procedures approved and recommended
by the provincial government (Bayerische Landesregierung).
2.2. Anatomical and Histological Analysis of Rats. Four 5-
months-old mut/mut rats from the breeding colony and
three age-matched unaffected littermates (controls) were
subjected to imaging procedures outlined below. Following
imaging, all rats were euthanized with carbon dioxide in
compliance with institutional requirements and subjected to
complete necropsy. Body and organ weights were measured
for every animal during necropsy. For histological analysis,
half of the adrenal gland was formalin-fixed, paraffin-
embedded, and evaluated using established criteria for
neoplasia of the rat endocrine system. The other half of
the adrenal gland was snap-frozen for molecular analyses.
To calculate the volume of the adrenal glands, we used the
ellipsoid formula, using the shortest diameter as the third
dimension.
2.3. Pet Imaging. The radiotracers 68Ga-DOTATOC and 11C-
Hydroxyephedrine (11C-HED)were synthesized according to
routine protocols.
PET radiotracers were injected intravenously via tail
veins (1 µg/18 MBq for 68Ga-DOTATOC; 5 MBq for 11C-
HED), and animals were imaged after sedation with isoflu-
rane, which was maintained during imaging procedures.
15min static PET images were acquired after 45min dis-
tribution for the longer lived PET tracer 68Ga-DOTATOC
(T1/2 = 67min); for the shorter lived 11C-HED (T1/2 =
20min) after 5min distribution time (Siemens Inveon
dedicated PET, Siemens, Erlangen), 10min static images
were acquired. Image reconstruction was performed with
an OSEM2d iterative algorithm into a 128 × 128 × 159
matrix with a voxel size of 0.776 × 0.776 × 0.796mm3. For
68Ga-DOTATOC images attenuation (10min point source
singles based), and scatter correction was applied to facilitate
absolute quantification. All data were corrected for random,
deadtime and decay.
2.4. Image Analysis. Image analysis was done with the
PMOD 2.9 software package (PMOD Technologies, Adliswil,
Switzerland). Spherical volumes of interest with a 4 mm
diameter were centrally placed into adrenals of the animals
used for the quantification studies (68Ga-DOTATOC and
11C-HED). Mean activity for 68Ga-DOTATOC studies was
then corrected by injected dose and weight of the animals to
derive SUV values (SUV = mean activity (kBq/mL) ∗weight
of the animals (g)/injected dose (kBq)). Semiquantitative
analysis for 11C-HED-studies was done by adrenal to liver
ratio using mean activity from an 8mmVOI centrally placed
in the liver.
2.5. RNA Extraction and Real-Time Quantitative RT-PCR.
For total RNA extraction from rat snap-frozen tissues, serial
40 µm tissue sections were subjected to manual macrodissec-
tion under the microscope to obtain adrenal medullary cells.
Macrodissected cells were resuspended in Trizol (Invitrogen,
Darmstadt, Germany) and processed following the manufac-
turer’s instructions. One microgram of total mRNAwas used
to synthesize first-strand cDNA using random hexamers.
Quantitative RT-PCR was done with TaqMan Assay-on-
Demand primers and probes for somatostatin receptors 2
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Table 1: Anatomical and functional quantification of the adrenals in MENX mutant rats compared to normal controls.
Right adrenal Left adrenal
[68Ga]DOTATOC
SUV
[11C]HED
adrenal/liver
Volume
(mm3)
Proliferation
index (range)
[68Ga]DOTATOC
SUV
[11C]HED
adrenal/liver
Volume
(mm3)
Proliferation index
(range)
Wild-type control rats (wt/wt)
N1 23.189 0.921 120.7 <2% 25.331 0.780 96.3 <2%
N2 15.177 0.725 98.35 <2% 15.703 0.720 91.62 <2%
N3 6.944 0.634 121.0 <2% 6.301 0.517 116.86 <2%
Mutant rats (mut/mut)
M1 21.479 1.370 162.24 6.6% (4.2–10.2) 24.077 1.326 168.94 16.7% (4.2–12.5)∗
M2 19.088 1.270 165.51 3.7% (1.6–5.7) 16.857 1.368 176.99 11.6% (4.3–18.9)∗
M3 23.797 2.193 638.93 13% (3.4–22.5)∗ 26.096 2.709 317.11 52% (50–54)
M4 28.173 1.361 132.67 n.d. 26.598 1.375 135.71 5.1% (2.8–8.3)
∗
Ki67 staining pattern is very heterogeneous: some areas have low, others have high Ki67 immunoreactivity.
(Sstr2), 3 (sstr3), and 5 (sstr5), norepinephrine transporter
(Slc6a2), and for ß2-microglobulin (B2M) as internal control
(Applied Biosystems). The relative mRNA expression level of
the targets genes was normalized for input RNA against B2M
gene expression in the sample. The relativemRNA expression
level (CR) of sstr2, sstr3, sstr5, and Slc6a2 in each sample
was calculated using the comparative cycle time (Ct) method
as CR = 2 − (Ct tissue of normal rat − Ct B2M) − (Ct
target tissue − Ct B2M). The average level of the target genes
mRNA in tissues of wt animals (+/+) is arbitrarily set to 1.
2.6. Immunohistochemistry. Immunohistochemistry was
performed on an automated immunostainer (VentanaMedi-
cal systems, Illkirch, France) according to the manufacturer’s
protocols withminor modifications, as described elsewhere
[10]. We used a monoclonal anti-p27Kip1 antibody
(BD Transduction Laboratories, Erembodegem, Belgium)
and the monoclonal MIB5 antibody (Dako, Glostrup,
Denmark) to detect the proliferation antigen Ki67, diluted
1 : 1000 and 1 : 500, respectively. Positive controls (tonsils)
were included in each staining run to confirm the adequacy
of the staining. Only distinct nuclear staining of tumor cells
was used for scoring the Ki67 immunoreactivity, which
was determined by counting at least 300 cells each case at
high power (400 folds) by a pathologist (A.P.). The number
of Ki67 positive cells per 100 adrenal medullary cells is
indicated as proliferative index. In the cases in which the
number of positive cells was not homogeneous in the adrenal
tissue, areas with the lowest and with the highest number
of positive cells were selected for counting (Table 1). Images
were recorded using a Hitachi camera HW/C20 installed in
a Zeiss Axioplan microscope with Intellicam software (Zeiss
MicroImaging, Jena, Germany). Adobe PhotoShop (San
Jose, CA, USA) was used for image processing.
2.7. Statistical Analysis. Comparisons between standardized
uptake values (SUVs) or adrenal to liver ratios measurements
in affected versus normal adrenal glands were carried out
using the two-sided Student’s t-test.
3. Results
3.1. Animals. Four mutant animals and three normal
controls were subjected to complete analysis with the
tracers (68Ga-DOTATOC and 11C-HED) (Table 1). All
adrenal lesions observed in our rats were confirmed by
histopathological examination as being pheochromocytomas
(Figure 1). The two adrenal glands of each animal were
analyzed separately. MENX adrenals were generally larger
(237mm3 ± 172) than normal adrenals (107mm3 ± 13).
3.2. PET. Adrenal DOTATOC and 11C-HED uptake was
detected in all animals (Figure 2). Comparisons between the
two groups of animals showed elevated uptake of 11C-HED
in all mutant rats compared to the controls: the adrenal
to liver ratios in mutant rats was 1.6 (±0.5) but was only
0.7 (±0.1) in normal rats (P = .002) (Table 1). Also 68Ga-
DOTATOC uptake was elevated in the adrenal glands of
mutant rats compared to the normal controls, although to
a lesser extent compared to 11C-HED uptake. Indeed, SUV
values for 68Ga-DOTATOC in pheochromocytoma were 23.3
(±3.9) while were 15.4 (±7.9) in normal control adrenals
(P = .03) (Figure 3 and Table 1).
3.3. Immunohistochemical Staining for p27Kip1 and Ki67.
Affected rats have a germline mutation in Cdkn1b that
makes the encoded protein highly unstable [11] and as a
consequence they have extremely reduced levels, or complete
loss, of p27Kip1 in their tissues, as previously reported
[9]. We performed immunohistochemical staining of the
adrenal glands of the 4 affected and the 3 normal control
animals subjected to imaging using an antibody specific for
p27Kip1. The results confirmed the low level of p27Kip1
expression in the adrenal medullary cells of the mutant
rats compared to those of wild-type control rats (Figure 1).
In humans, several normal and neoplastic tissues show an
inverse relationship between p27Kip1 expression and the
proliferation activity of the tumor cells [12, 13]. Moreover, in
human pheochromocytoma the proliferation index is among
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Figure 1: Histopathological and immunohistopathological comparison of MENX mutant rats ((a), (c), (e)) versus normal control rat
((b), (d), (f)). (a) Histology of the right adrenal gland of the normal rat N2 (H&E). (b) Histology of the left adrenal gland of the
mutant rat M2 (H&E). (c) Immunohistochemical staining for p27Kip1 of the same gland as in (a). (d) Immunohistochemical staining
for p27Kip1 of the same gland as in (b). (e) Immunohistochemical staining for the proliferation marker Ki67 of the same gland as in a. (f)
Immunohistochemical staining for the proliferation marker Ki67 of the same gland as in (b). M, adrenal medulla. Original magnifications:
(a), (b) ×20; (c)–(f) ×160.
the parameters that help defining the malignant potential of
the tumor [14, 15]. Therefore, we determined the prolifer-
ative index of the rat tumor cells by immunohistochemical
staining for the proliferation marker Ki67 (MIB-5 antigen)
to determine whether the low p27Kip1 levels had an effect
on cell proliferation. We found that the average proliferative
index in all tumors, except one, varied between 3.7% and
16.7% (Table 1). The exception was the left adrenal tumor
of rat M3 that showed a percentage of Ki67 immunopositive
cells over 50% (Table 1), which is suggestive of a malignant
phenotype. The distribution of Ki67 immunoreactivity in the
tumor tissue was not homogeneous, with areas of lower and
others of higher proliferative activity. The proliferation rate
of all tumors was higher than that of normal rat adrenal
glands (Ki67 immunoreactivity <1%).
3.4. Real-Time Quantitative RT-PCR for Somatostatin
Receptor Genes and Noradrenalin Transporter Gene. Neu-
roendocrine tumor cells often express on their mem-
brane somatostatin receptors (Sstr). Therefore, radiolabeled
somatostatin analogues are useful in the clinicalmanagement
of neuroendocrine malignancies and also in their detection
by functional imaging. Among the different Sstr subtypes
identified (Sstr1-Sstr5), Sstr2 shows the highest affinity for
the somatostatin analogues such as 68Ga-DOTATOC, fol-
lowed by Sstr5 and Sstr3 [16]. Recently, standardized uptake
values (SUV) with 68Ga-DOTATOC-PET in patients with
neuroendocrine tumors have been found to correlate with
the expression of the SSTR2 protein by the tumor cells [17].
To determine if there might be a correlation between uptake
values in MENX rats and expression of the somatostatin
receptors, we quantified the level of the rat Sstr2, Sstr3,
and Sstr5 genes by Real-Time quantitative RT-PCR in the
adrenal lesions subjected to functional imaging. Similarly,
we also analyzed the expression of the Slc6a2 gene encoding
for the norepinephrine transporter, the protein implicated
in the reuptake of monoamines, including 11C-HED (the
other tracer we used), in chromaffin cells. The results show
that only the expression of the Sstr2 gene encoding, the
somatostatin receptor subtype having the highest affinity
for 68Ga-DOTATOC, is slightly but significantly increased in
affected versus control adrenals (2.1-fold ±0.8; P = .0214,
two-tailed U test). In contrast, the mRNA level of the Sstr3
(80.5 ± 0.4; P = .63), Sstr5 (1.6 fold ±1; P = .093), and
Slc6a2 (1.5 fold ±1.4; P = .42) genes are not significantly
different in affected versus wild-type control rats (Figure 4).
4. Discussion
Our study shows that functional imaging can visualize
noninvasively the pheochromocytomas that develop in the
context of the MENX rat syndrome. These findings set
the standard for future preclinical testing of novel targeted
therapies for neuroendocrine tumors in this animal model.
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Figure 2: Imaging of rat adrenal glands. (a) 11C-HED in aMENX animal. (b) 11C-HED in a normal animal. (c) 68Ga-DOTATOC in a MENX
animal. (d) 68Ga-DOTATOC in a normal animal. The arrows indicate the adrenal glands.
11C-HED gave the best imaging results (Table 1) sug-
gesting that the norepinephrine transport system might
be a more suitable target to visualize MENX-associated
pheochromocytoma by PET-imaging. Quantitative RT-PCR
showed that the expression of the Slc6a2 gene (nore-
pinephrine transporter) is comparable between mutant and
wild-type animals. This indicates that the level of expression
of Slc6a2 mRNA does not highly correlate with 11C-HED
tracer uptake, as affected rats show a much higher uptake
of the tracer than control rats despite having an mRNA
level similar to the controls. Therefore, in our model system
the level of expression of the Slc6a2 gene is not predictive
of the protein amount and/or of the biological activity
of the norepinephrine transporter system. Of course we
cannot exclude that differences might exist between mutant
and control rats in the final amount of norepinephrine
transporter protein or in its activity.
Imaging with the somatostatin receptor analogue
68Ga-DOTATOC demonstrated a moderate increase in the
uptake of this tracer in affected rat adrenal glands compared
to wild-type control glands. This is in agreement with the
increased expression level of the Sstr2 gene in mutant com-
pared to normal rat adrenals. However, Ga-68-DOTATOC
uptake was lower than we expected in the rat tumor tissues,
and quantification of the somatostatin receptor protein in
these cells might be required to fully clarify this issue.
Immunohistochemical staining confirmed the low levels
of p27Kip1 in the mutant rat adrenals and showed a
moderate to elevated proliferation index of the tumors. The
proliferation rate of the rat pheochromocytomas was not
homogeneous within the lesions and varied between 1.6 and
22.5%, with one adrenal gland (of animal M3) having a
proliferation index above 50% (Table 1). Immunoreactivity
for Ki67 in the rat lesions was higher than that displayed
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Figure 3: Summary of the uptake values. Uptake values were obtained with the two indicated tracers in normal (Wt) and in mutant rats
(Mut). ∗, P = .0016.
by human pheochromocytoma, usually lower than 3.5%
[14, 18, 19]. In patients a high proliferation rate is most
frequently found in malignant tumors [7]. Therefore, the
MENX pheochromocytoma with high Ki67 immunoreactiv-
ity has characteristics suggestive of an aggressive behaviour.
No metastatic spread was observed both by histology and
by PET in any of the affected animals subjected to imaging,
maybe because it had not yet taken place as the mutant rats
were relatively young (5 months old) and their average life-
span is 10 ± 2 months. In any case, the relatively high Ki67
proliferation index makes MENX an interesting model of
aggressive behaviour in pheochromocytoma.
One of the PET-tracers used in staging and restaging of
human pheochromocytoma is the norepinephrine analogue
11C-HED (Hydroxyephedrine). Compared to 123I-MIBG, a
norepinephrine analogue commonly used for conventional
scintigraphy including SPECT, 11C-HED is a more polar
molecule resulting in faster excretion and therefore in the
possibility of early, time-saving imaging acquistion [20]. In
addition to 11C-HED, 68Gallium labelled somatostatin ana-
logues (such as 68Ga-DOTATOC) are clinically suitable for
the imaging of human pheochromocytoma [21]. Both nore-
pinephrine uptake and somatostatin receptor binding have
been used as targets for internal delivery of beta emitting iso-
topes for palliative treatment ofmetastasized paragangliomas
or pheochromocytomas [22]. Further investigation of such
targeted radionuclide therapy approaches in the MENX rat
model might improve their application in humans.
For both tracers (11C-HED and 68Ga-DOTATOC),
slightly different methods of quantification of the PET signal
were chosen. For 11C-HED, liver to tumor ratios were chosen
according to clinically established methods for diagnosis
of pheochromocytoma using 131I-MIBG-scintigraphy [23].
This approach quantifies the norepinephrine transporter
system, which also mediates 11C-HED internalization. Since
68Ga-DOTATOC-PET did not show relevant tracer uptake
in the rat liver, it is impossible to delineate this organ
on the scans. Therefore, a quantification factor has been
established to yield absolute activity concentrations and
derived standardized uptake values in vivo without the need
of a reference region.
Internal radiotherapy of pheochromocytoma with 131I-
MIBG has been used with some success in reducing tumor
bulk, thereby attenuating the symptoms associated to cat-
echolamines oversecretion and alleviating pain. However, a
curative potential has generally not been observed. Addi-
tionally, cytoreductive chemotherapy has been applied with
limited success [24]. In this context, novel compounds
for targeted therapy are needed. The ongoing molecular
chacterization ofMENX-associated pheochromocytoma and
precursor lesions will identify new specific pathways involved
in tumor development. If suitable, these novel molecular
targets will be used for small animal PET imaging, to further
characterize the MENX animal model and to evaluate new
targeted treatment modalities.
The mutant p27 protein associated with the MENX
syndrome is degraded very fast by the proteasome [11] so
that its level in the tissues of affected rats is extremely reduced
or totally absent [9]. In humans, the expression level of
p27 is also frequently reduced or absent in many tumor
types [25], and this downregulation is achieved mainly
through accelerated proteasome-mediated proteolysis [26],
establishing a parallel with the situation in MENX rat
tumors. Due to the tumor suppressive function of p27,
restoring its levels in tumor cells may reinstate control of cell
proliferation, hence the interest in compounds that might
specifically interfere with p27 degradation [27]. MENX-
affected animals represent an ideal preclinical model for
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Figure 4: Expression of relevant genes in adrenal glands. Real-time TaqMan RT-PCR ofmRNA extracted from normal rat adrenal tissue (wt)
and rat tumor tissue (Mut). The ΔCt method was used to normalize gene expression values to the ß2-microglobulin housekeeping control
gene and to a reference calibrator RNA. Dots represent individual RNA samples. The bar indicates the average gene expression value. The
average value for the normal adrenal tissues was arbitrarily set to 1. ∗, P = .0214.
investigating the effect of novel proteasome-inhibitor drugs
on pheochromocytoma. Based on our findings, monitoring
of the efficacy of such compounds against the tumor can be
achieved by performing repeated 11C-HED-PET imaging.
In conclusion, the MENX rat model, that develops
pheochromocytoma with 100% penetrance, in conjunction
with the imaging approaches described here, might be
a powerful preclinical model system to evaluate differ-
ent targeted therapy strategies like, for example, targeted
radionuclide therapies or novel proteasome inhibitors in
pheochromocytoma. Tracer uptake was able to distinguish
affected from normal adrenal glands, indicating that the
resolution of the method is appropriate for the precise
localization of the rat adrenal tumors. This high resolution
8 International Journal of Molecular Imaging
in combination with specific PET tracers will allow us
to precisely monitor the dynamics of tumor development
following treatment of young affected rats with therapeutic
compounds with antitumor activity. Further studies will
extend the range of suitable PET-tracers that depict distinct
pathways of pheochromocytoma tumorigenesis, such as
tracers investigating additional cell surface markers (such
as integrins or other neuroendocrine-specific receptors) or
metabolic pathways (e.g., 18F-DOPA).
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